Outlook Therapeutics (OTLK) Asset Utilization Ratio (2016 - 2025)

Outlook Therapeutics (OTLK) posted quarterly Asset Utilization Ratio of 0.38 for Q3 2025, down 7.44% quarter-over-quarter from 0.41 in Q2 2025.

Outlook Therapeutics (OTLK) Asset Utilization Ratio (2016 - 2025) Analysis & Trends

Outlook Therapeutics (OTLK) has reported Asset Utilization Ratio for 5 consecutive years, with 0.38 the latest figure, recorded in Q3 2025.

In Q3 2025, Asset Utilization Ratio changed N/A year-over-year to 0.38; the TTM figure through Sep 2025 stood at 0.38 (changed N/A YoY), while the FY2025 annual figure was 0.06, changed N/A from the prior year.
Asset Utilization Ratio declined to 0.38 in Q3 2025 per OTLK's latest filing, from 0.41 in the prior quarter.
Across five years, Asset Utilization Ratio topped out at 0.41 in Q2 2025 and bottomed at 0.38 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.38
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.20
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.69
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	0.90
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.13
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.54
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.13
10	Outlook Therapeutics	88.50 Mn	77.26 Mn	-8,265.00	-

Download Data